Anhui Anke BioTech Group (300009)

Shenzhen
Currency in CNY
8.60
+0.02(+0.23%)
Closed
300009 Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
High dividend Yield
Fair Value
Day's Range
8.508.68
52 wk Range
7.4111.77
Key Statistics
Edit
Bid/Ask
8.60 / 8.60
Prev. Close
8.58
Open
8.65
Day's Range
8.5-8.68
52 wk Range
7.41-11.77
Volume
13.95M
Average Volume (3m)
15.32M
1-Year Change
-14.09%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
300009 Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Impressive gross profit margins
Show more

Anhui Anke BioTech Group Company Profile

Anhui Anke Biotechnology (Group) Co., Ltd. develops, produces, and markets pharmaceutical products in China and internationally. The company offers human growth hormone for injection under the Ansomone name; and recombinant human interferon alpha 2b lyophilized powder, liquid, and prefilled syringe for injection, as well as recombinant human interferon alpha 2b cream, eye drop, and suppository under the Anterferon name. It provides anti-sperm antibody, semen leukocyte peroxidase staining, one-time semen processing, sperm hypo-osmotic staining, sperm life detection, sperm staining detection, sperm acrosin detection, sperm DNA fragmentation staining, and leptin and immunohistochemical diagnostic kits. In addition, the company offers adhesive plasters, oral solutions, topical preparations, and ointments; peptide APIs; beauty care products, including anti-aging, masks, and essential liquids; mouthwash; and synthetic drugs in the form of oral powders, dripping pills, and tablets and capsules. Further, it provides autosomal, sex chromosome, autosomal and sex chromosome combination, and other kits; paternity testing set packages; tumor biological immunotherapy products; and DNA testing professional services. Additionally, the company offers monoclonal antibody drugs, such as Trastuzumab to treat patients with breast and gastric cancers under the ANTRASTUIN brand; Bevacizumab for the treatment of non-small cell lung cancer; and anti-PD1 for advanced cancers. The company was founded in 2000 and is based in Hefei, China.

Employees
2986
Market
China

Compare 300009 to Peers and Sector

Metrics to compare
300009
Peers
Sector
Relationship
P/E Ratio
18.2x22.4x−0.6x
PEG Ratio
9.840.200.00
Price/Book
3.6x2.0x2.6x
Price / LTM Sales
5.2x6.7x3.1x
Upside (Analyst Target)
25.6%32.8%52.8%
Fair Value Upside
Unlock22.3%8.4%Unlock

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 0.47
Dividend Yield
4.03%
Industry Median 1.40%
Annualized payout
0.3500
Paid unevenly
5-Years Growth
+29.47%
Growth Streak

Earnings

Latest Release
Oct 25, 2024
EPS / Forecast
-- / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

FAQ

What Is the Anhui Anke BioTech Group (300009) Stock Price Today?

The Anhui Anke BioTech Group stock price today is 8.60

What Stock Exchange Does Anhui Anke BioTech Group Trade On?

Anhui Anke BioTech Group is listed and trades on the Shenzhen stock exchange.

What Is the Stock Symbol for Anhui Anke BioTech Group?

The stock symbol for Anhui Anke BioTech Group is "300009."

Does Anhui Anke BioTech Group Pay Dividends? What’s The Current Dividend Yield?

The Anhui Anke BioTech Group dividend yield is 4.08%.

What Is the Anhui Anke BioTech Group Market Cap?

As of today, Anhui Anke BioTech Group market cap is 14.35B.

What is Anhui Anke BioTech Group Earnings Per Share?

The Anhui Anke BioTech Group EPS is 0.47.

What Is the Next Anhui Anke BioTech Group Earnings Date?

Anhui Anke BioTech Group will release its next earnings report on Mar 27, 2025.

From a Technical Analysis Perspective, Is 300009 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.